| scholarly article | Q13442814 |
| P50 | author | Jeanne Lusher | Q14084239 |
| P2093 | author name string | S Alexander | |
| D Nugent | |||
| S W Pipe | |||
| P2860 | cites work | Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency | Q28303496 |
| The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation | Q35882779 | ||
| Prophylaxis in rare coagulation disorders -- factor XIII deficiency | Q36449902 | ||
| ETRO Working Party on Factor XIII questionnaire on congenital factor XIII deficiency in Europe: status and perspectives. Study Group | Q40955198 | ||
| Clinico-hematologic profile of factor XIII-deficient patients | Q46770303 | ||
| Delayed umbilical bleeding--a presenting feature for factor XIII deficiency: clinical features, genetics, and management. | Q52862051 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 316-321 | |
| P577 | publication date | 2009-12-15 | |
| P1433 | published in | Haemophilia | Q15753375 |
| P1476 | title | Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study | |
| P478 | volume | 16 |
| Q38100849 | A child with acquired factor XIII deficiency: case report and literature review |
| Q38038687 | Biology of Factor XIII and clinical manifestations of Factor XIII deficiency |
| Q27026565 | Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency? |
| Q42688987 | Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study |
| Q42182012 | Efficacy and safety of prophylactic treatment with plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency |
| Q45885874 | Evaluation of the FXIII deficiency prophylaxis intervals in large number of FXIII deficiency patients from Iran. |
| Q84458890 | Induction of hemodialysis therapy in a case with factor XIII deficiency |
| Q37246427 | Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P® |
| Q38688608 | Minimal factor XIII activity level to prevent major spontaneous bleeds |
| Q36906072 | New developments in the management of congenital Factor XIII deficiency |
| Q36719655 | Nonclinical analysis of the safety, pharmacodynamics, and pharmacokinetics of plasma-derived human FXIII concentrate in animals |
| Q44868346 | Perioperative course of FXIII in children undergoing major surgery |
| Q42178072 | Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency |
| Q48543476 | Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency. |
| Q30767399 | Rare coagulation factor deficiencies: a countrywide screening data from India |
| Q49966943 | Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. |
| Q38743779 | Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results. |
| Q42791520 | Revisiting hemophilia management in acute medicine |
| Q31139049 | Safety of Factor XIII Concentrate: Analysis of More than 20 Years of Pharmacovigilance Data |
| Q38231336 | The burden and management of FXIII deficiency |
| Q37990479 | The hope and reality of long-acting hemophilia products |
| Q38056460 | The rare inherited coagulation disorders |
| Q44251818 | Treatment of refractory hemorrhage with Factor XIII in a patient with hemophilia A with inhibitor |
| Q46309743 | Use of Factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures |
| Q51016864 | [Factor XIII : Pharmacodynamic and pharmacokinetic characteristics]. |
Search more.